NCT02919501 - Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 27, 2016

Primary Completion Date

April 27, 2017

Study Completion Date

April 27, 2017

Conditions

Depressive Disorder, Major

Interventions

DRUG

Vortioxetine (IV)

17 mg, solution for infusion, administered, over 2 hours as single dose

OTHER

Placebo (IV)

Saline: isotonic sodium chloride, administered, over 2 hours as single dose

DRUG

Vortioxetine (tablet)

10 mg, tablets, oral administration once daily for 15 days (open labelled)

Trial Locations (7)

EE1019, Tallinn

EE1020, Tallinn

FI1040, Helsinki

FI1041, Helsinki

FI1030, Kuopio

FI1009, Pori

FI1027, Turku